Technavio Announces the Publication of its Research Report Leukemia Therapeutics Market 2016-2020
Technavio recognizes the following companies as the key players in the leukemia therapeutics market: F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.
Browse full report with TOC@ https://marketreportscenter.com/reports/403840/global-leukemia-therapeutics-market-2016-2020
Commenting on the report, an analyst from Technavios team said: One of the key trends for market growth will be the rise in the development of combination therapies. Combination therapies for the treatment of leukemia were available only in the form of combination chemotherapy drugs. The some of the approved combinations are chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. Also, it has been observed that vendors are showing more interest in the development of combination therapies to treat various leukemias.
According to the report, application for expanded indication approvals will be a key driver for market growth. There has been an increase in the R&D activities going on for the re-positioning of already marketed drugs for the new indications in the global leukemia therapeutics market. This concept of re-positioning came into practice in the early 1990s and is originate from the possibility of different diseases could be sharing common molecular pathways. The companies are conducting clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is low risk, high reward strategy, this should increase the scope of treatment and hence, help in the increased market penetration.
Further, the report states that financial and infrastructural constraints will be a major challenge for the market. The financial and infrastructural constraints associated with leukemia medications is high, especially in emerging nations. Most of the branded medications are not available in these regions as the companies have not received approvals. For instance, Venclexta, a product of AbbVie and F. Hoffmann-La Roche, received approval in April 2016 in the US, Europe, and Japan. The drug is yet to be launched in other regions. This reduces the accessibility of drugs for the individuals in these regions. Also, most of the branded therapies are costly. The high cost of therapy is a major factor resulting in treatment withdrawal by individuals. The R&D costs of developing such drugs are usually high. Therefore, manufacturers are forced to pass on these costs to the buyer. However, this inhibits the adoption of the drugs because the end-users perceive treatment costs as a burden.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/403840
Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.
Technavios analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.
The market is divided into the following segments based on geography:
Technavio’s report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
To Get Discount On The Report @ https://marketreportscenter.com/request-discount/403840
Connect for more details:
Market Reports Center